Chemed Co. (CHE) Shares Bought by WINTON GROUP Ltd

WINTON GROUP Ltd grew its position in shares of Chemed Co. (NYSE:CHE) by 9.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,828 shares of the company’s stock after purchasing an additional 577 shares during the period. WINTON GROUP Ltd’s holdings in Chemed were worth $2,182,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Fort L.P. bought a new stake in shares of Chemed in the 2nd quarter valued at about $120,000. Cerebellum GP LLC bought a new stake in shares of Chemed in the 3rd quarter valued at about $148,000. Tower Research Capital LLC TRC lifted its stake in shares of Chemed by 70.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 544 shares of the company’s stock valued at $175,000 after acquiring an additional 224 shares during the last quarter. We Are One Seven LLC bought a new stake in shares of Chemed in the 3rd quarter valued at about $228,000. Finally, Hollencrest Capital Management bought a new stake in shares of Chemed in the 3rd quarter valued at about $231,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

In related news, VP Naomi C. Dallob sold 5,500 shares of the business’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $317.23, for a total transaction of $1,744,765.00. Following the transaction, the vice president now owns 11,122 shares in the company, valued at approximately $3,528,232.06. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Donald E. Saunders sold 300 shares of the business’s stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $319.22, for a total value of $95,766.00. Following the transaction, the director now owns 8,701 shares in the company, valued at approximately $2,777,533.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,806 shares of company stock worth $5,902,345. 4.82% of the stock is owned by company insiders.

A number of equities research analysts have recently weighed in on CHE shares. Bank of America started coverage on Chemed in a research note on Friday, October 12th. They issued a “buy” rating and a $390.00 target price for the company. Royal Bank of Canada boosted their target price on Chemed to $321.00 and gave the company a “market perform” rating in a research note on Monday, July 30th. Zacks Investment Research downgraded Chemed from a “buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, ValuEngine downgraded Chemed from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $332.00.

Shares of NYSE:CHE opened at $314.11 on Tuesday. Chemed Co. has a 1 year low of $227.14 and a 1 year high of $335.99. The stock has a market cap of $5.08 billion, a P/E ratio of 58.60, a price-to-earnings-growth ratio of 2.78 and a beta of 1.23. The company has a current ratio of 1.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.23.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Monday, October 29th. The company reported $3.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.80 by $0.27. Chemed had a return on equity of 35.13% and a net margin of 11.73%. The company had revenue of $444.15 million for the quarter, compared to the consensus estimate of $445.16 million. During the same quarter in the previous year, the business earned $2.15 EPS. Chemed’s revenue was up 6.4% compared to the same quarter last year. On average, analysts expect that Chemed Co. will post 11.41 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Monday, November 12th will be issued a dividend of $0.30 per share. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 0.38%. Chemed’s dividend payout ratio is presently 22.39%.

COPYRIGHT VIOLATION NOTICE: “Chemed Co. (CHE) Shares Bought by WINTON GROUP Ltd” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.wkrb13.com/2018/11/13/chemed-co-che-shares-bought-by-winton-group-ltd.html.

About Chemed

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Featured Story: What is Liquidity?

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply